---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040802"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:19:23.846861+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Imunon Q3 net loss $3.5M; OVATION 2 shows 33% PFS improvement, OS benefit

## Summary
- Net loss of $3.5M ($0.37 per share) vs $6.1M loss in Q3 2022; operating expenses down 38% to $3.9M.
- Cash and equivalents $19.5M as of Sept 30, 2023; expects $1.8M from NJ NOL sales.
- Interim OVATION 2 data: PFS improved ~33% in treatment arm; OS improved ~9 months; median PFS 23.7 months with PARP inhibitor combo vs 15.7 months control.
- Enrolled first patient in Phase 1/2 trial of IMNN-001 + bevacizumab at MD Anderson; IND filing for IMNN-101 COVID booster on track for Q1 2024.
- Entered CRADA with NIAID for Lassa virus vaccine evaluation.

## SEC filing metadata
- accession: 0001493152-23-040802
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315223040802/0001493152-23-040802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315223040802/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040802
- JSON: https://secwatch.observer/filing/0001493152-23-040802.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040802.txt

## Key facts
- Earnings Releases
  Imunon, Inc. reported financial results for the three and nine months ended September 30, 2023.
  - Period: the three and nine months ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, Imunon, Inc. issued a press release reporting its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315223040802/0001493152-23-040802-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.